LianBio (NASDAQ:LIAN) Trading Up 5%

Shares of LianBio (NASDAQ:LIAN) rose 5% on Monday . The company traded as high as $0.32 and last traded at $0.32. Approximately 201,363 shares changed hands during trading, a decline of 81% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.30.

LianBio Stock Performance

The business has a 50 day moving average of $0.32 and a two-hundred day moving average of $2.17. The firm has a market cap of $32.96 million, a P/E ratio of -0.38 and a beta of 0.23.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Donald L. Hagan LLC grew its position in shares of LianBio by 37.3% in the fourth quarter. Donald L. Hagan LLC now owns 20,600 shares of the company’s stock valued at $92,000 after purchasing an additional 5,600 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in LianBio by 63.5% in the 4th quarter. Axxcess Wealth Management LLC now owns 27,126 shares of the company’s stock valued at $121,000 after purchasing an additional 10,536 shares during the period. Finally, Affinity Asset Advisors LLC grew its holdings in LianBio by 462.2% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,779,694 shares of the company’s stock valued at $16,895,000 after buying an additional 3,107,337 shares in the last quarter. 74.85% of the stock is owned by institutional investors.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.